Oruka Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
ORKA$109.50+4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Operations and Comprehensive Loss
(In thousands, except share and per share data)
| Operating expenses | |
|---|---|
| Research and development (1) | $75,060 |
| General and administrative (2) | 13,063 |
| Total operating expenses | 88,123 |
| Loss from operations | (88,123) |
| Other income (expense) | |
| Interest income | 5,863 |
| Interest expense (3) | (1,468) |
| Other income, net | 4 |
| Total other income, net | 4,399 |
| Net loss | (83,724) |
| Unrealized loss on marketable securities | (41) |
| Comprehensive loss | $(83,765) |
| Net loss per share attributable to common stockholders, basic and diluted | $(3.87) |
| Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted | $(3,873.25) |
| Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | $(322.81) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 16,789,362 |
| Weighted-average shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted | 495 |
| Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | 51,946 |
| (1) | Includes related party amount of $42,640 for the period from February 6, 2024 (inception) to December 31, 2024 |
| (2) | Includes related party amount of $1,364 for the period from February 6, 2024 (inception) to December 31, 2024 |
| (3) | Includes related party amount of $1,468 for the period from February 6, 2024 (inception) to December 31, 2024 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.